Antithrombin III in animal models of sepsis and organ failure

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 1, 1998, Pages 61-69

  Dickneite, Gerhard ^a,b  

^a Preclin Pharmacol Dept Centeon P   (Germany)

^b Centeon Pharma GmbH   (Germany)

Author keywords

Animal experimentation; Bacterial infection; Combination therapy; Disseminated intravascular coagulation; Septic shock

Indexed keywords

ANTITHROMBIN III;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; MULTIPLE ORGAN FAILURE; NONHUMAN; OXYGEN CONSUMPTION; PREECLAMPSIA; PRIORITY JOURNAL; SEPSIS; SUBSTITUTION THERAPY; XENOTRANSPLANTATION;

EID: 0031950793     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995824     Document Type: Article

References (55)

1. Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL. Antithrombin: The principle inhibitor of thrombin. Semin Thromb Hemostas 1994;20:353-372
2. Rosenberg JS, McKenna P, Rosenberg RD. Inhibitors of human factor IXa by human antithrombin-heparin cofactor. J Biol Chem 1975;250:8883-8888
3. Stead N, Kaplan AP, Rosenberg RD. The inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 1976;251:6481-6488
4. Damus PS, Hicks M, Rosenberg RD. A generalized view of heparin's anticoagulant action. Nature 1973;246:355-357
5. Rao LVM, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995;85:121-129
6. Highsmith RF, Rosenberg RD. The inhibition of human plasmin by human antithrombin-heparin-cofactor. J Biol Chem 1974; 249:4335-4338
7. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975;292:146-151
8. Seegers WH. Antithrombin III. Theory and clinical applications. Am J Clin Pathol 1978;69:367-374
9. Bone RC. Definitions for sepsis and organ failure. Crit Care Med 1992;20:724-726
10. Ménache D, Grossman BJ, Jackson CM. Antithrombin III: Physiology, deficiency, and replacement therapy. Transfusion 1992; 32:580-588
11. Matthias FR. Hemostasis imbalance with sepsis. Pathogenetic value and therapeutic implications. Intensivmed 1996;33:1-4
12. Thijs LG, de Boer JP, de Groot MCM, Hack CE. Coagulation disorders in septic shock. Intensive Care Med 1993;19:8-15
13. Mann LT, Jensenius JC, Simonsen M, Abildgaard U. Antithrombin III: Protection against death after injection of thromboplastin. Science 1969;166:517-518
14. Deventer JH, Büller HR, ten Cate JW, Aarden L, Hack EC, Sturk A. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520-2526
15. Triantaphyllopoulus DC. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb Haemostas 1984;51:232-235
16. Emerson TE. Protection against disseminated intravascular coagulation and death by antithrombin III in the Escherichia coli endotoxemic rat. Circ Shock 1987;21:1-13
17. Redens TB, Emerson Jr TE. Antithrombin III treatment limits disseminated intravascular coagulation in endotoxemia. Circ Shock 1989;28:49-58
18. Redens TB, Leach WJ, Bogdanoff DA, Emerson TE. Synergistic protection from lung damage by combining antithrombin III and alpha-1-proteinase inhibitor in the E. coli endotoxic sheep pulmonary dysfunction model. Circ Shock 1988;26:15-26
19. Hauptman JG, Hassouna HI, Bell TG, Penner JA, Emerson TE. Efficacy of antithrombin III in endotoxin-induced disseminated intravascular coagulation. Circ Shock 1988;25:111-122
20. Gomez C, Paramo JA, Colucci M, Rocha H. Effect of heparin and/or antithrombin III on the generation of endotoxin-induced plasminogen activator inhibitor. Thromb Haemostas 1989;62: 694-698
21. Dickneite G, Pâques EP. Protection of DIC-induced mortality in Klebsiella pneumoniae-infected LPS-treated rats by antithrombin III. In: Müller-Berghaus G, ed. DIC: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. Amsterdam: Excepta Medica; 1993:215-219
22. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effects of antithrombin III (AT III) and TRP49-modified AT III on plasma levels of 6-keto-PGF1α in rats. Thromb Res 1995; 80:201-208
23. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996;270:L921-L930
24. Dickneite G, Leithäuser B. The effect of antithrombin III (Kybernin®) on porcine septic shock. Ann Hematol 1996;72:102
25. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE. Antithrombin III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988;26:227-235
26. Dickneite G, Pâques EP. Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella pneumoniae induced sepsis. Thromb Haemostas 1993;2:98-102
27. Kessler CM, Tang ZCh, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: Substantial reduction in mortality and morbidity. Blood 1997;89:4393-4401
28. Kouz J, Czech J, Nicolay U, Dickneite G. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits. Haemostasis 1996;26:179-186
29. Phillips TF, Mammen EF, Selik NR, et al. Experimentelle Verbrauchskoagulopathie - Behandlung mit Antithrombin III. Med Welt 1984;35:1022-1026
30. Mammen EF, Miyakawa T, Phillips TF, Assarian GS, Brown JM, Murano G. Human antithrombin concentrates and experimental disseminated intravascular coagulation. Semin Thromb Haemostas 1985;11:373-383
31. Dickneite G, Seiffge D. Efficacy of C1 inhibitor on capillary leakage and septic shock in the rat. In: E Faist, Baue AE, Schildberg FW, ed. The Immune Consequences of Trauma, Shock and Sepsis. Lengerich: Pabst Science Publishers; 1996:44-50
32. Naess F, Waage A, Roeise O, Stadaas JO, Aasen AO. Effects of a combined drug regimen on tumour necrosis factor and plasma kallikrein activity in experimental endotoxaemia. Eur J Surg 1994;160:77-86
33. Inoue Y, Kohno S, Miyazaki T, Yamaguchi K. Effect of a platelet activating factor antagonist and antithrombin III on septicemia and endotoxemia in rats. Tohoku J Exp Med 1991;163:175-185
34. Emerson Jr TE. Effects of purified fibronectin alone and combined with immunoglobulin G or antithrombin III on survival during gram-negative peritonitis or endotoxemia in rats. J Trauma 1987;27:1201-1266
35. Shinyama H, Yamanaga K, Akira T, et al. Antithrombin III prevents blood pressure elevation and proteinuria induced by high salt intake in pregnant stroke-prone spontaneously hypertensive rats. Biol Pharm Bull 1996;19:819-823
36. Schmidt B, Davis P, La Pointe H, Monkman S, Coates G, de SA D. Thrombin inhibitors reduce intrapulmonary accumulation of fibrinogen and procoagulant activity of bronchoalveolar lavage fluid during acute lung injury induced by pulmonary overdistention in newborn piglets. Ped Res 1996;39:798-804
37. Neely AN, Miller RG, Holder IA. Proteolytic activity and fatal gram-negative sepsis in burned mice: Effect of exogenous proteinase inhibition. Infect Immunity 1994;62:2158-2164
38. Bleeker WK, Agterberg J, Rigter G, Hack CE, Gool JV. Protective effect of antithrombin III in acute experimental pancreatitis in rats. Dig Dis Sci 1992;37:280-285
39. Yamaguchi H, Weidenbach H, Lührs H, Lerch MM, Dickneite G, Adler G. Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. Gut 1997;40:531-535
40. Takeshita K, Arakawa K, Okamoto M, et al. The anticoagulant effect of antithrombin III on hyperacute xenograft rejection. Transplant Proc 1996;28:631-632
41. Heckl-Östreicher B, Wosnik A, Kirschfink M. Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Transplantation 1996; 62:1693-1696
42. Fujiwara I, Nakajima H, Arakawa K, Akioka K, Takeshita K, Oka T. Prolongation of xenograft survival by soluble complement receptor type 1 and antithrombin-III combination therapy. Transplant Proc 1996;28:685-686
43. Piper RD, Cook DJ, Bone RC, Sibbald WJ. Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 1996;24:2059-2070
44. Dellinger RP (chairman). Proceedings of a conference on the future of sepsis research. American College of Chest Physicians, 1996
45. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989;163:1404-1411
46. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59:895-904
47. Voigt A, Sawitzky D, Zeichhardt H. Cellular receptor structures for pseudorabies virus are blocked by antithrombin III. Med Microbiol Immunol 1995;184:97-103
48. Emerson TE. Antithrombin III replacement in animal models of acquired antithrombin III deficiency. Blood Coag Fibrinolysis 1994;5:S37-S45
49. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest 1992;101:816-823
50. Fourrier F, Chopin C, Huart J, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104:882-888
51. Obertacke U, Kleinschmidt C, Jochum M, et al. Reduction of shock-related complications and pulmonary microvascular permeability by continuous application of antithrombin III (140% serum activity) for 4 days after trauma - preliminary results of a prospective clinical study. Langenbeck Arch Chir 1993;(Suppl II):1287-1288
52. Siebeck M, Schorr M, Welcker K, Waldner H, Gippner-Steppert C, Jochum M. Antithrombin III und lokale Serumgabe als adjuvante Therapie bei Patienten mit diffuser, sekundärer Peritonitis. In: Bennet D, ed. Ninth Eur. Congr. Intensive Care Med. Bologna: Monduzzi Editore; 1996:385-390
53. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: A randomized study. Thromb Res 1985;39:81-89
54. Maki M, Terao T, Ikenoue T, et al. Clinical evaluation of antithrombin III concentrates (BI 6.013) for disseminated intravascular coagulation in obstetrics. Gynecol Obstet Invest 1987; 23:230-240
55. Lamy M, Eisele B, Keinecke H.-O., Delvos U, Thijs LG. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial. Ninth European Congress on Intensive Care Medicine. Glasgow, September 1996